Lindbrook Capital, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$0
-100.0%
0
-100.0%
0.00%
Q2 2023$1,832
+18.4%
54
+25.6%
0.00%
Q1 2023$1,547
-56.1%
43
-45.6%
0.00%
Q4 2022$3,52179
+2533.3%
0.00%
Q3 2022$03
-66.7%
0.00%
Q2 2022$0
-100.0%
9
-82.7%
0.00%
Q1 2022$2,000
-96.2%
52
-94.7%
0.00%
-100.0%
Q3 2021$53,000
+152.4%
990
-1.0%
0.01%
+180.0%
Q1 2021$21,0000.0%1,000
-38.2%
0.01%
-16.7%
Q2 2020$21,0001,6180.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2021
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders